Diego Infante-Ventura

Mr. Diego Infante-Ventura

Servicio de Evaluación del Servicio Canario de Salud, Santa Cruz, Canary Islands, Spain
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
YÁYolanda Álvarez-Pérez
Yolanda Álvarez-Pérez
ARAmado Rivero-Santana
Amado Rivero-Santana
LPLilisbeth Perestelo-Pérez
Lilisbeth Perestelo-Pérez
ADAndrea Duarte
Andrea Duarte
VRVanesa Ramos-García
Vanesa Ramos-García
PSPedro Serrano-Aguilar
Pedro Serrano-Aguilar
Background: Meditation is defined as a form of cognitive training that aims to improve attentional and emotional self-regulation. This systematic review aims to evaluate the available scientific evidence on the effectiveness and safety of mantra-based meditation techniques (MBM), in comparison to passive or active controls, or other active treatment, for the management of mental health symptoms. Methods: MEDLINE, EMBASE, Cochrane Library, and PsycINFO databases were consulted up to April 2021. Randomised controlled trials regarding meditation techniques mainly based on the repetition of mantras, such as transcendental meditation or others, were included. Results: MBM, compared to control conditions, was found to produce significant small-to-moderate effect sizes in the reduction of anxiety (g = −0.46, IC95%: −0.60, −0.32; I2 = 33%), depression (g = −0.33, 95% CI: −0.48, −0.19; I2 = 12%), stress (g = −0.45, 95% CI: −0.65, −0.24; I2 = 46%), post-traumatic stress (g = −0.59, 95% CI: −0.79, −0.38; I2 = 0%), and mental health-related quality of life (g = 0.32, 95% CI: 0.15, 0.49; I2 = 0%). Conclusions: MBM appears to produce small-to-moderate significant reductions in mental health; however, this evidence is weakened by the risk of study bias and the paucity of studies with psychiatric samples and long-term follow-up.

14 November 2022 in European Journal of Neurology
Verified
Journal Article
Closed access
BLBeatriz León‐Salas
Beatriz León‐Salas
YGYadira González‐Hernández
Yadira González‐Hernández
DIDiego Infante-Ventura
Diego Infante-Ventura
AAAythami de Armas‐Castellano
Aythami de Armas‐Castellano
JGJavier García‐García
Javier García‐García
MTMaría M. Trujillo‐Martín
María M. Trujillo‐Martín

10 November 2022 in European Urology Open Science
Verified
Journal Article
Open access
TPTasmania del Pino-Sedeno
Tasmania del Pino-Sedeno
DIDiego Infante-Ventura
Diego Infante-Ventura
ACAythami de Armas Castellano
Aythami de Armas Castellano
PPPedro de Pablos-Rodríguez
Pedro de Pablos-Rodríguez
ARAntonio Rueda-Domínguez
Antonio Rueda-Domínguez
MTMaría M. Trujillo-Martín
María M. Trujillo-Martín
Context: Prostate cancer (PCa) is the second most common type of cancer in men. Individualized risk stratification is crucial to adjust decision-making. A variety of molecular biomarkers have been developed in order to identify patients at risk of clinically significant PCa (csPCa) defined by the most common PCa risk stratification systems. Objective: The present study aims to examine the effectiveness (diagnostic accuracy) of blood or urine-based PCa biomarkers to identify patients at high risk of csPCa. Evidence acquisition: A systematic review of the literature was conducted. Medline and EMBASE were searched from inception to March 2021. Randomized or nonrandomized clinical trials, and cohort and case-control studies were eligible for inclusion. Risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. Pooled estimates of sensitivity, specificity, and area under the curve were obtained. Evidence synthesis: Sixty-five studies (N = 34 287) were included. Not all studies included prostate-specific antigen-selected patients. The pooled data showed that the Prostate Health Index (PHI), with any cutoff point between 15 and 30, had sensitivity of 0.95–1.00 and specificity of 0.14–0.33 for csPCa detection. The pooled estimates for SelectMDx test sensitivity and specificity were 0.84 and 0.49, respectively. Conclusions: The PHI test has a high diagnostic accuracy rate for csPCa detection, and its incorporation in the diagnostic process could reduce unnecessary biopsies.

21 December 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PPPedro De Pablos-Rodríguez
Pedro De Pablos-Rodríguez
TPTasmania del Pino-Sedeno
Tasmania del Pino-Sedeno
DIDiego Infante-Ventura
Diego Infante-Ventura
AAAythami de Armas-Castellano
Aythami de Armas-Castellano
MBMiguel Ramírez Backhaus
Miguel Ramírez Backhaus
MTMaría del Mar Trujillo-Martín
María del Mar Trujillo-Martín
Prostate cancer (PCa) is the second most common cancer in men and the fifth leading cause of death from cancer. The possibility of sarcopenia being a prognostic factor in advanced PCa patients has recently become a subject of interest. The aim of the present study was to evaluate the prognostic value of sarcopenia in advanced prostate carcinoma. A systematic review was conducted in Medline, EMBASE, and Web of Science (March, 2021). The quality of studies was assessed using the Quality in Prognosis Studies tool. Meta-analyses for overall, cancer-specific, and progression-free survival were performed. Nine studies (n = 1659) were included. Sarcopenia was borderline associated with a shorter overall survival (HR = 1.20, 95% CI: 1.01, 1.44, P = 0.04, I2 = 43%) but was significantly associated with progression-free survival (HR = 1.61, 95% CI: 1.26, 2.06, P < 0.01; k = 3; n = 588). Available evidence supports sarcopenia as an important prognostic factor of progression-free survival in patients with advanced PCa. However, sarcopenia has a weak association with a shorter overall survival. The evidence on the role of sarcopenia in prostate-cancer-specific survival is insufficient and supports the need for further research. Patient summary: The literature was reviewed to determine whether the loss of muscle mass (sarcopenia) affects the survival in patients with advanced PCa. Patients with advanced PCa and sarcopenia were found to have a shorter progression-free survival (the length of time during and after treatment of a cancer that the patient lives with the disease but it does not get worse), but sarcopenia did not have much influence on the overall survival and cancer-specific survival (the length of time from either the date of diagnosis or the start of treatment to the date of death due to the cancer).

22 January 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
TPTasmania Del Pino-Sedeño
Tasmania Del Pino-Sedeño
DIDiego Infante-Ventura
Diego Infante-Ventura
DHDiego Hernández-González
Diego Hernández-González
YGYadira González-Hernández
Yadira González-Hernández
BLBeatriz González de León
Beatriz González de León
FAFrancisco Javier Acosta Artiles
Francisco Javier Acosta Artiles
Introduction: Current evidence reveals concerning rates of non-adherence to antidepressant treatment, possibly influenced by various relevant determinants such as sociodemographic factors or those related to the health system and their professionals. The aim of this paper is to review the scientific evidence on sociodemographic and clinical predictors of adherence to pharmacological treatment in patients diagnosed with a depressive disorder.Methods: a systematic review (SR) was conducted. The search for a previous SR was updated and de novo searches were performed in Medline, EMBASE, Web of Science (WoS) and PsycInfo (last 10 years). The risk of bias was assessed using the Cochrane tool for non-randomized studies—of Exposure (ROBINS-E). Meta-analyses were conducted.Results: Thirty-nine studies (n = 2,778,313) were included, 24 of them in the meta-analyses. In the initiation phase, no association of adherence was found with any of the predictors studied. In the implementation and discontinuation phases, middle-aged and older patients had better adherence rates and lower discontinuation rates than younger ones. White patients adhered to treatment better than African-American patients.Discussion: Age and ethnicity are presented as the predictive factors of pharmacological adherence. However, more research is needed in this field to obtain more conclusive results on other possible factors.Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023414059], identifier [CRD42023414059]

30 December 2022 in Health Expectations
Verified
Journal Article
Open access
JRJanet Delgado Rodríguez
Janet Delgado Rodríguez
VRVanesa Ramos-García
Vanesa Ramos-García
DIDiego Infante-Ventura
Diego Infante-Ventura
JSJosé Carlos Suarez‐Herrera
José Carlos Suarez‐Herrera
ARAntonio Rueda‐Domínguez
Antonio Rueda‐Domínguez
MTMaría del Mar Trujillo‐Martín
María del Mar Trujillo‐Martín
Introduction: Scalp cooling (SC) aims to prevent chemotherapy‐induced alopecia. The goal of this systematic review is to tackle ethical, legal, organizational and social issues related to SC.Methods: A critical appraisal of the literature was carried out using a systematic review design. MEDLINE, Embase and Web of Science databases were searched up until 2 June 2021. Studies addressing these aspects in English or Spanish were considered. Representatives of both patient associations and professional scientific societies related to the topic participated in the design of the protocol and the review of the findings.Results: A total of 17 studies were included. Articles were critically appraised using the MMAT and SANRA. Findings were organized into four categories: (1) ethical aspects focused on equal access, gender equity and doctor–patient communication supported by Patient Decision Aids (PtDAs); (2) patient perspective and acceptability; (3) professional perspective and acceptability; (4) organizational aspects focused on accessibility and feasibility.Conclusion: Cancer patients' expectations when using SC need to be adjusted to reduce the potential distress associated with hair loss. PtDAs could help patients clarify their values and preferences regarding SC. Equal access to technology should be guaranteed.Patient or Public Contribution: In this systematic review, the representatives of the patient associations (Ms. María Luz Amador Muñoz of the Spanish Association Against Cancer [AECC] and Ms. Catiana Martinez Cánovas of the Spanish Breast Cancer Federation [FECMA]) participated in the review of the study protocol, as well as in the results, discussion and conclusions, making their contributions. In the type of design of these studies (systematic reviews), it is not usual to have the direct participation of patients, but in this one, we have done so, as it is a systematic review that is part of a report of the Spanish Network of Health Technology Assessment Agencies (ETS).